EP0349797B1 - Composition pharmaceutique stabilisée contenant de l'acétylcystéine - Google Patents

Composition pharmaceutique stabilisée contenant de l'acétylcystéine Download PDF

Info

Publication number
EP0349797B1
EP0349797B1 EP89110619A EP89110619A EP0349797B1 EP 0349797 B1 EP0349797 B1 EP 0349797B1 EP 89110619 A EP89110619 A EP 89110619A EP 89110619 A EP89110619 A EP 89110619A EP 0349797 B1 EP0349797 B1 EP 0349797B1
Authority
EP
European Patent Office
Prior art keywords
ascorbic acid
acetylcysteine
ascorbate
acetyl cysteine
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89110619A
Other languages
German (de)
English (en)
Other versions
EP0349797A1 (fr
Inventor
Fritz Dr. Stanislaus
Fritz-Heinrich Klemm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Deutschland GmbH
Original Assignee
Klinge Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Pharma GmbH and Co filed Critical Klinge Pharma GmbH and Co
Priority to AT89110619T priority Critical patent/ATE81000T1/de
Publication of EP0349797A1 publication Critical patent/EP0349797A1/fr
Application granted granted Critical
Publication of EP0349797B1 publication Critical patent/EP0349797B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Definitions

  • the invention relates to a stabilized pharmaceutical preparation, in particular a stabilized drug containing N-acetylcysteine, and the use of ascorbic acid or ascorbate to stabilize the same.
  • N-acetylcysteine has an expectorant effect in various diseases of the lungs and bronchi.
  • Acetylated cysteine is characterized by increased stability compared to the starting substance cysteine in the body. This is due to the fact that the orally ingested active ingredient is not only reversibly bound to protein as a free substance, but also via disulfide bridges or is firmly incorporated into proteins. The unstable disulfide bond between N-acetylcysteine and proteins can therefore be regarded as a protective form.
  • the active ingredient does not enjoy such protection in aqueous solution or dispersion, especially not if, according to the recommendation in the medication package insert, the commercially available granules are dissolved in water, tea or fruit juices for ingestion. Then there is a risk that, especially when dissolved in a warm medium, the active substance will decompose.
  • the extent of the decomposition is particularly strong if the active ingredient after dissolution in e.g. warm water or tea is not taken straight away, but left to stand for some time. For example, It is found that when a medicinal product containing N-acetyl is dissolved in tea heated to approx. 70 ° C under conditions such as those in a thermos flask, thermos flask or on a hotplate, a significant amount of the active ingredient is obtained after approx is decomposed.
  • JP 49/92219 describes the stabilization of aqueous ascorbic acid solutions by adding non-therapeutic amounts of N-acetylcysteine and sulfite.
  • a stabilization of aqueous N-acetylcysteine solutions by ascorbic acid cannot be derived from the above-mentioned prior art, especially taking into account the respective oxidation potentials of ascorbic acid and N-acetylcysteine.
  • Ascorbic acid has a standard oxidation potential of -0.115 volts at pH 5.2 (30 ° C) and of -0.140 volts at pH 4.7 (30 ° C) (Stewart, PJ, Tucker, IG, Aust. J. , Hosp. Pharm., 15 (2), 1985, page 111 ff.). It can be assumed that the oxidation mechanism of N-acetylcysteine is comparable to that of cysteine and thus a standard oxidation potential similar to that of cysteine can be assumed for N-acetylcysteine. Cysteine has a standard oxidation potential of +0.220 volts (25 ° C) (see above publication by P.J. Stewart et al.).
  • the object of the present invention is to provide a stabilized medicament containing N-acetylcysteine.
  • the drug to be stabilized containing N-acetylcysteine is in solid form or as an aqueous solution or dispersion, and is preferably brought into aqueous solution for use on humans. It is preferred to dissolve the N-acetylcysteine-containing drug for ingestion in a warm medium, in which it is
  • the form stabilized according to the invention essentially retains its effectiveness even when left to stand for a longer period of time.
  • the amounts by weight of ascorbic acid or a salt thereof added for stabilization can vary in the range from 5 to 100 parts by weight, preferably from 10 to 50 parts by weight, in each case based on 100 parts by weight of N-acetylcysteine.
  • the amount of ascorbic acid or ascorbate is particularly preferably 25 parts by weight per 100 parts by weight of N-acetylcysteine.
  • the invention also encompasses the use of ascorbic acid or a salt thereof for the stabilization of medicaments containing N-acetyl.
  • N-acetylcysteine achieved according to the invention is surprising insofar as it was not to be expected due to the oxidation potentials of N-acetylcysteine on the one hand and ascorbic acid on the other hand.
  • the stabilizing effect according to the invention is generally evident when N-acetylcysteine is dissolved in an aqueous medium and left to stand for some time. This effect is particularly pronounced when the drug is dissolved in warm tea; in this case, the decomposition of the active ingredient, which is accelerated by the presence of tea ingredients such as flavones, tannins, etc., is largely prevented. The decomposition of N-acetylcysteine is thus significantly reduced due to the stabilizing effect of ascorbic acid. This effect is all the more advantageous because the physiological tolerability and safety of ascorbic acid cannot be disputed, a fact that is not true for all antioxidants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1 - Médicament contenant de la N-acétylcystéine stabilisée, caractérisé en ce qu'il comprend une quantité thérapeutiquement active de N-acétylcystéine et, comme seul stabilisant, de l'acide ascorbique ou un ascorbate.
2 - Médicament selon la revendication 1, caractérisé en ce qu'il se présente sous forme solide, de solution ou de dispersion aqueuse.
3 - Médicament selon les revendications 1 ou 2, caractérisé en ce que pour l'administration à l'homme il est amené sous forme de solution aqueuse.
4 - Médicament selon les revendications 1 à 3, caractérisé en ce que l'acide ascorbique ou l'ascorbate sont présents dans un rapport pondéral de 5 à 100 parties pour 100 parties de N-acétylcystéine.
5 - Médicament selon la revendication 4, caractérisé en ce que l'acide ascorbique ou l'ascorbate sont présents dans un rapport pondéral de 10 à 50 parties pour 100 parties de N-acétylcystéine.
6 - Médicament selon la revendication 4, caractérisé en ce que l'acide ascorbique ou l'ascorbate sont présents dans un rapport pondéral de 25 parties pour 100 parties d'acétylcystéine.
7 - Utilisation de l'acide ascorbique ou de l'ascorbate pour la stabilisation de médicaments contenant de la N-acétylcystéine comme seul stabilisant, la N-acétylcystéine étant présente dans une quantité thérapeutiquement active.
8 - Utilisation selon la revendication 7, dans laquelle le médicament est présent sous forme de substance solide, de solution ou de dispersion aqueuse.
EP89110619A 1988-06-30 1989-06-12 Composition pharmaceutique stabilisée contenant de l'acétylcystéine Expired - Lifetime EP0349797B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89110619T ATE81000T1 (de) 1988-06-30 1989-06-12 Stabilisierte, n-acetylcysteinhaltige arzneimittelzubereitung.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3822096 1988-06-30
DE3822096A DE3822096A1 (de) 1988-06-30 1988-06-30 Stabilisierte arzneimittelzubereitung

Publications (2)

Publication Number Publication Date
EP0349797A1 EP0349797A1 (fr) 1990-01-10
EP0349797B1 true EP0349797B1 (fr) 1992-09-30

Family

ID=6357629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89110619A Expired - Lifetime EP0349797B1 (fr) 1988-06-30 1989-06-12 Composition pharmaceutique stabilisée contenant de l'acétylcystéine

Country Status (5)

Country Link
EP (1) EP0349797B1 (fr)
AT (1) ATE81000T1 (fr)
DE (2) DE3822096A1 (fr)
ES (1) ES2043959T3 (fr)
GR (1) GR3005848T3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007236B (el) * 2009-12-07 2011-04-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, Νεα φαρμακευτικη συνθεση κοκκιων ν - ακετυλοκυστεϊνης και μεθοδος παραγωγης αυτων

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4103360A1 (de) * 1991-02-05 1992-08-06 Koehler Peter Medikament zur linderung und heilung von asthma bronchiale und anderen lungenerkrankungen
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4406261C2 (de) * 1993-08-31 1996-07-04 Deutsches Krebsforsch Verwendung von Thiolverbindungen zur Verminderung der Körperfettmenge
DE4329857C2 (de) * 1993-09-03 1995-08-24 Deutsches Krebsforsch Verbindung zur Stärkung des Immunsystems und von Immunreaktionen
IN2000KO00299A (fr) * 1999-05-28 2005-11-18 Johnson & Johnson Consumer
TR200900881A2 (tr) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tadı ve kokusu maskelenmiş stabil farmasötik bileşimler
US10682324B2 (en) * 2015-01-27 2020-06-16 Florengale, Llc Healing topical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336176C2 (de) * 1972-07-14 1987-01-22 Richard Albert Silverspring Passwater, Md. Als Nahrungs- und Futter-Zusatzmittel geeignetes Mittel mit Antialterungs-, Tumorverhütungs- und Antitumorwirkung
CH667590A5 (it) * 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Band 96, Nr. 9, 01 März 1982, Columbus, OH (US); R.R.PFISTER et al., Seite 62, Nr. 62950a. *
INVEST. OPHTALMOL. VIS. SCI., Band 25, Nr. 3, September 1981; Seiten 486-490. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007236B (el) * 2009-12-07 2011-04-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, Νεα φαρμακευτικη συνθεση κοκκιων ν - ακετυλοκυστεϊνης και μεθοδος παραγωγης αυτων

Also Published As

Publication number Publication date
DE58902357D1 (de) 1992-11-05
ES2043959T3 (es) 1994-01-01
ATE81000T1 (de) 1992-10-15
EP0349797A1 (fr) 1990-01-10
GR3005848T3 (fr) 1993-06-07
DE3822096A1 (de) 1990-01-04

Similar Documents

Publication Publication Date Title
DE69001088T2 (de) Oral zur verabreichendes arzneimittel zur gastrointestinalen waesche, insbesondere zur diagnostischen verwendung oder als kathartisches laxans.
DE602005002495T2 (de) Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat
DE69000645T2 (de) Bei kuehlschranktemperatur stabile waessrige folinatloesung sowie verfahren zu deren herstellung.
DE68903988T2 (de) Acetylcystein enthaltende mundloesliche arzneimittel.
EP0185210B1 (fr) Utilisation de dérivés dipeptidiques pour la préparation de médicaments pour le traitement des malades atteints de sclérose latérale amyotrophique
EP0349797B1 (fr) Composition pharmaceutique stabilisée contenant de l'acétylcystéine
DE1915798C3 (de) Antacidum-Präparat in Form einer wäßrigen Suspension
CH642261A5 (de) Arzneipraeparat auf der basis eines salzes der acetylsalicylsaeure und einer basischen aminosaeure und verfahren zu seiner herstellung.
EP1073469B1 (fr) Solutions stables de mitoxantrone
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
DE2349538C2 (de) Arzneimittel zur Behandlung von Lebererkrankungen
DE3700379C2 (fr)
DE69804169T2 (de) Oral anzuwendende flüssige Arzneilösung
DE3619426A1 (de) Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
EP0363502B1 (fr) Formulation liquide contenant du bismuth, procédé pour la préparer et son utilisation
EP1150660B1 (fr) Formulation effervescente pharmaceutique contenant du metamizol
DE1902148A1 (de) Farbstabilisiertes Vitamin Centhaltendes Stoffgemisch
DE69000621T2 (de) Pentamidinloesungen.
DE2209526B2 (de) Coronartherapeutikum in Form von Gelatine-BeiBkapseln
DE60219770T2 (de) Krebsmittel
DE10238161A1 (de) Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation
DE3780702T2 (de) Verwendung von etodolac zur senkung des blutgehalts an harnsaeure.
DE3440140C2 (de) Verwendung von Thiamphenicol gegen die Gewöhnung an zentral wirkende Analgetika
DE2102889C3 (de) Verwendung von SuIf adimidin und Pyrimethamin
DE3030314A1 (de) Arzneimittel auf sulfonamidbasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19891120

17Q First examination report despatched

Effective date: 19900921

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 81000

Country of ref document: AT

Date of ref document: 19921015

Kind code of ref document: T

ITF It: translation for a ep patent filed
ET Fr: translation filed
REF Corresponds to:

Ref document number: 58902357

Country of ref document: DE

Date of ref document: 19921105

REG Reference to a national code

Ref country code: GB

Ref legal event code: 777B

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3005848

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19930518

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2043959

Country of ref document: ES

Kind code of ref document: T3

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 89110619.7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990510

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19990528

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19990601

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990602

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19990607

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990617

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990623

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990630

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000612

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000613

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000630

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000630

BERE Be: lapsed

Owner name: KLINGE PHARMA G.M.B.H.

Effective date: 20000630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000612

EUG Se: european patent has lapsed

Ref document number: 89110619.7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010228

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20010101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20020304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050612

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080626

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080624

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20080626

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: FUJISAWA DEUTSCHLAND GMBH

Free format text: KLINGE PHARMA GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG#BERG-AM-LAIM-STRASSE 129#D-81673 MUENCHEN (DE) -TRANSFER TO- FUJISAWA DEUTSCHLAND GMBH#BERG-AM-LAIM-STRASSE 129#81673 MUENCHEN (DE)

Ref country code: CH

Ref legal event code: PUE

Owner name: TEMMLER WERKE GMBH

Free format text: ASTELLAS DEUTSCHLAND GMBH#GEORG-BRAUCHLE-RING 64-66#80992 MUENCHEN (DE) -TRANSFER TO- TEMMLER WERKE GMBH#WEIHENSTEPHANER STR. 28#81673 MUENCHEN (DE)

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA

Ref country code: CH

Ref legal event code: PUE

Owner name: FUJISAWA GMBH

Free format text: FUJISAWA DEUTSCHLAND GMBH#BERG-AM-LAIM-STRASSE 129#81673 MUENCHEN (DE) -TRANSFER TO- FUJISAWA GMBH#LEVELINGSTRASSE 12#81673 MUENCHEN (DE)

Ref country code: CH

Ref legal event code: PUE

Owner name: ASTELLAS DEUTSCHLAND GMBH

Free format text: ASTELLAS PHARMA GMBH#GEORG-BRAUCHLE-RING 64-66#80992 MUENCHEN (DE) -TRANSFER TO- ASTELLAS DEUTSCHLAND GMBH#GEORG-BRAUCHLE-RING 64-66#80992 MUENCHEN (DE)

Ref country code: CH

Ref legal event code: PFA

Owner name: ASTELLAS PHARMA GMBH

Free format text: FUJISAWA GMBH#LEVELINGSTRASSE 12#81673 MUENCHEN (DE) -TRANSFER TO- ASTELLAS PHARMA GMBH#GEORG-BRAUCHLE-RING 64-66#80992 MUENCHEN (DE)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL